Gavin Newsom Jokes He’ll Legalize Marijuana As ‘Leader Of The Free World’ And Get People ‘High On Patriotism’ Amid Federal Shutdown

October 3, 2025

California marijuana tax increase delay meets campaign-style theater as Gavin Newsom, savoring the vacuum of a federal shutdown, hopped on X to declare himself “leader of the free world” and vow to legalize cannabis. It was parody with a politician’s palate: salty, sweet, and served in all caps. Still, timing is a flavor all its own. The bit landed the same day a new state law kicked in to postpone a planned cannabis tax hike for three years—a nod to the battered California cannabis market and a rare win in the long, strange saga of cannabis taxation. You could almost hear the cork pop in dispensary back rooms, where margins are thin, rent is not, and the illicit market still eats lunch without paying the tip.

“GOOD NEWS PATRIOTS!… LEGALIZE CANNABIS!… CRIME WILL STAY LOW AND EVERYONE WILL BE HIGH ON PATRIOTISM.”

Taxes versus theater, and who pays for the show

Newsom’s satire—free eggs, hair gel subsidies, the whole carnival—works because the policy subtext is dead serious. California’s delay of a cannabis tax hike is more than legislative housekeeping; it’s triage. Legal cannabis revenue relies on a regulated market that actually lives long enough to pay taxes. Every extra percentage point can push shoppers back to the sidewalk economy, where no one files quarterly. The three-year tax reprieve acts like a pressure valve on licensed operators gasping under costs, compliance, and competition. If you’ve ever watched a budtender explain why a legal eighth costs more than a trunk sale across town, you know the plot: taxation without value breeds attrition, not loyalty. A strategic pause won’t solve everything—oversupply, local bans, enforcement gaps—but it helps. And it sets the table for a fuller meal: genuine marijuana policy reform that aligns price, safety, and access so the legal market doesn’t have to fight with one hand tied behind its back.

Rescheduling is not legalization—so let’s not confuse appetizers with the main course

While Washington argues over the lights bill, another thread hangs in the air: rescheduling cannabis from Schedule I to Schedule III. A president can nod, agencies can grind, and the bureaucracy can spit out a new label. Useful? Sure. Schedule III could soften 280E’s brutal tax penalties, ease research, and give the industry cleaner accounting. But let’s be clear: rescheduling is not legalization. It doesn’t fix interstate commerce, expungements, or the contradiction of “state-legal yet federally illicit.” It’s a breadcrumb on a long walk. Meanwhile, the political theater rolls on—Trump coy about timing, allies framing rescheduling as historic, skeptics rolling their eyes. Outside the echo chamber, patients keep doing what patients do: reporting relief. Chronic pain, sleepless nights, prescription cutbacks—these are not abstracts; they’re lived realities reflected in surveys and clinics, the same realities explored in Medical Marijuana Effectively Treats Chronic Pain And Helps Patients Reduce Prescription Drug Use, Survey Shows. And as the hemp-derived CBD craze continues—especially among seniors—the culture has already moved past the Beltway’s training wheels.

The messy map: banking, badges, and a patchwork of rules

Banking reform looms like a stubborn doorman: everyone knows the party’s better inside, but only a few get in. Even a GOP Senate sponsor has mused that rescheduling would be an “important domino” for cannabis banking. Maybe. But on the ground, contradictions run the show. In Florida, courts finally said what drivers have felt for years: the smell of marijuana alone can’t be the skeleton key to your glovebox. That’s a notable civil liberties crack in a wall of pretext stops, as laid out in Florida Court Blocks Police From Using The Smell Of Marijuana Alone To Search Vehicles. Travel northwest and the tone changes. In prohibition country, storefronts flirting with the edges get the hammer, with headlines like Kansas Law Enforcement Launches Raids Against ‘Brazen’ Cannabis Sales In Storefronts. Same plant, different planets. The result is a whiplash market where risk is priced locally, capital is scarce, and every regulator swears their spreadsheet is the gold standard.

California’s tax delay, then, reads like pragmatic harm reduction for a maturing industry stuck in a fractured federation. You need short-term oxygen before you can run a marathon. If the state wants legal cannabis revenue to stabilize—funding schools, treatment, public health—it must keep licensed operators solvent and attractive against the illicit discount rack. That means coherent cannabis taxation, faster local licensing, smarter enforcement that targets bad actors without sandbagging the compliant, and federal policy that lets money move like it’s the 21st century. In the background, the reform horizon is broadening beyond cannabis. New York lawmakers are already holding hearings on psychedelics, noting medical potential and careful guardrails, a conversation captured in New York Lawmakers Hold Hearing Psilocybin’s Medical Benefits Amid Broader Debate Over Psychedelics Reform. Culture starts the fire; policy chases the smoke.

So here we are, somewhere between a joke and a sea change. Newsom’s post worked because it punctured the absurdity of a shutdown while winking at a future where cannabis policy is boring, responsible, and fully legal—like alcohol with a better hangover profile. The California marijuana tax increase delay is a quiet move with loud consequences, a small mercy for operators who’ve been paying cover while the band tunes up. If you want this market to grow up, keep the theater fun, keep the policy sober, and let the numbers, not the slogans, drive the night. And if you’re curious to explore compliant, high-quality options shaped by this evolving landscape, browse our shop at https://thcaorder.com/shop/.

Leave a Reply

Get 15% Off!

Join our mailing list to get code!

Subscribe

Get Weekly Discounts &  Holiday Coupons directly to your email!

    FDA disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure, or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your healthcare professional about potential interactions or other possible complications before using any product. The Federal Food, Drug, and Cosmetic Act requires this notice.

    Select the fields to be shown. Others will be hidden. Drag and drop to rearrange the order.
    • Image
    • SKU
    • Rating
    • Price
    • Stock
    • Availability
    • Add to cart
    • Description
    • Content
    • Weight
    • Dimensions
    • Additional information
    Click outside to hide the comparison bar
    Compare
    Home
    Shopping
    Account